{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:46:44Z","timestamp":1794534404698,"version":"4.9.1"},"reference-count":42,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Foundation of Strategic Research (SSF)","award":["SM21-0042"],"award-info":[{"award-number":["SM21-0042"]}]},{"name":"Swedish Foundation of Strategic Research (SSF)","award":["ID22-0048"],"award-info":[{"award-number":["ID22-0048"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>CD40-targeting therapies can enhance the dendritic cell priming of tumor-specific T cells and repolarize intratumoral macrophages to alleviate the tumoral immunosuppressive environment and remodel the extracellular matrix. Mitazalimab is a potent agonistic CD40 monoclonal IgG1 antibody currently under clinical development. This study used RNA sequencing of blood samples from a subset of patients from a Phase I trial with mitazalimab (NCT02829099) to assess peripheral pharmacodynamic activity. We found that mitazalimab induced transient peripheral transcriptomic alterations (at 600 \u00b5g\/kg and 900 \u00b5g\/kg dose administered intravenously), which mainly were attributed to immune activation. In particular, the transcriptomic alterations showed a reduction in effector cells (e.g., CD8+ T cells and natural killer cells) and B cells peripherally with the remaining cells (e.g., dendritic cells, monocytes, B cells, and natural killer cells) showing transcription profiles consistent with activation. Lastly, distinct patient subgroups based on the pattern of transcriptomic alterations could be identified. In summary, the data presented herein reinforce the anticipated mode of action of mitazalimab and support its ongoing clinical development.<\/jats:p>","DOI":"10.3390\/cells12192365","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T03:04:18Z","timestamp":1695783858000},"page":"2365","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9517-5864","authenticated-orcid":false,"given":"Hampus","family":"Andersson","sequence":"first","affiliation":[{"name":"Alligator Bioscience AB, 223 81 Lund, Sweden"},{"name":"Department of Immunotechnology, Lund University, 223 81 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aastha","family":"Sobti","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, 223 81 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Gomez","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, 223 81 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago Pico","family":"de Coa\u00f1a","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, 223 81 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet Vijay","family":"Ambarkhane","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, 223 81 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"H\u00e4gerbrand","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, 223 81 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Enell","family":"Smith","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, 223 81 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Lindstedt","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, 223 81 Lund, Sweden"},{"name":"Department of Immunotechnology, Lund University, 223 81 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-1250","authenticated-orcid":false,"given":"Peter","family":"Ellmark","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, 223 81 Lund, Sweden"},{"name":"Department of Immunotechnology, Lund University, 223 81 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101134","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The Association between CD8+ Tumor-Infiltrating Lymphocytes and the Clinical Outcome of Cancer Immunotherapy: A Systematic Review and Meta-Analysis","volume":"41","author":"Li","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"612271","DOI":"10.3389\/fimmu.2021.612271","article-title":"Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins","volume":"12","author":"Liot","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1146\/annurev.iy.12.040194.004313","article-title":"The CD40 Antigen and Its Ligand","volume":"12","author":"Banchereau","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.smim.2009.05.010","article-title":"The Role of CD40 and CD40L in Dendritic Cells","volume":"21","author":"Ma","year":"2009","journal-title":"Semin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 Agonist Antibodies in Cancer Immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/14712598.2021.1934446","article-title":"Rationale and Clinical Development of CD40 Agonistic Antibodies for Cancer Immunotherapy","volume":"21","author":"Deronic","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I Interferon-Mediated Tumor Immunity and Its Role in Immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning Cold Tumors Hot: From Molecular Mechanisms to Clinical Applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-15-1032","article-title":"IFN-\u03b3 and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma","volume":"6","author":"Long","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Djureinovic, D., Wang, M., and Kluger, H.M. (2021). Agonistic CD40 Antibodies in Cancer Treatment. Cancers, 13.","DOI":"10.3390\/cancers13061302"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"A422","DOI":"10.1136\/jitc-2021-SITC2021.389","article-title":"389 Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy","volume":"9","author":"Weiss","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/1078-0432.CCR-14-0913","article-title":"The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-Cell\u2013Dependent Tumor Immunity","volume":"21","author":"Mangsbo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ijc.32141","article-title":"First-in-Human Study with Intratumoral Administration of a CD40 Agonistic Antibody, ADC-1013, in Advanced Solid Malignancies","volume":"145","author":"Irenaeus","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10637-022-01319-2","article-title":"A Phase 1 Study of Intravenous Mitazalimab, a CD40 Agonistic Monoclonal Antibody, in Patients with Advanced Solid Tumors","volume":"41","author":"Moreno","year":"2022","journal-title":"Investig. New Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical Activity and Immune Modulation in Cancer Patients Treated with CP-870,893, a Novel CD40 Agonist Monoclonal Antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 Agonistic Monoclonal Antibody APX005M (Sotigalimab) and Chemotherapy, with or without Nivolumab, for the Treatment of Metastatic Pancreatic Adenocarcinoma: An Open-Label, Multicentre, Phase 1b Study","volume":"22","author":"Varadhachary","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s00262-021-02932-5","article-title":"The Human Anti-CD40 Agonist Antibody Mitazalimab (ADC-1013; JNJ-64457107) Activates Antigen-Presenting Cells, Improves Expansion of Antigen-Specific T Cells, and Enhances Anti-Tumor Efficacy of a Model Cancer Vaccine In Vivo","volume":"70","author":"Deronic","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_19","unstructured":"Pantano, L., Hutchinson, J., Barrera, V., Piper, M., Khetani, R., Daily, K., Malai Perumal, T., Kirchner, R., and Steinbaugh, M. (2023, September 18). DEGreport: Report of DEG Analysis. Available online: http:\/\/lpantano.github.io\/DEGreport\/."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Love, M.I., Huber, W., and Anders, S. (2014). Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2. Genome Biol., 15.","DOI":"10.1186\/s13059-014-0550-8"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Blighe, K. (2023, September 18). EnhancedVolcano: Publication-Ready Volcano Plots with Enhanced Colouring and Labeling 2023. Available online: https:\/\/github.com\/kevinblighe\/EnhancedVolcano.","DOI":"10.32614\/CRAN.package.ggvolcano"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v061.i06","article-title":"NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set","volume":"61","author":"Charrad","year":"2014","journal-title":"J. Stat. Softw."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: A Comprehensive Gene Set Enrichment Analysis Web Server 2016 Update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"H\u00e4nzelmann, S., Castelo, R., and Guinney, J. (2013). GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data. BMC Bioinform., 14.","DOI":"10.1186\/1471-2105-14-7"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining Cell Type Abundance and Expression from Bulk Tissues with Digital Cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/bioinformatics\/btl117","article-title":"Pvclust: An R Package for Assessing the Uncertainty in Hierarchical Clustering","volume":"22","author":"Suzuki","year":"2006","journal-title":"Bioinformatics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","article-title":"Cross-Tissue Single-Cell Landscape of Human Monocytes and Macrophages in Health and Disease","volume":"54","author":"Mulder","year":"2021","journal-title":"Immunity"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune Modulation with Weekly Dosing of an Agonist CD40 Antibody in a Phase I Study of Patients with Advanced Solid Tumors","volume":"10","author":"Antonia","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2012.09251.x","article-title":"A Phase 1 Study of Lucatumumab, a Fully Human Anti-CD40 Antagonist Monoclonal Antibody Administered Intravenously to Patients with Relapsed or Refractory Multiple Myeloma","volume":"159","author":"Bensinger","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","article-title":"Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study","volume":"21","author":"Johnson","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fgene.2020.00019","article-title":"High-Throughput Transcriptome Profiling in Drug and Biomarker Discovery","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrg2934","article-title":"RNA Sequencing: Advances, Challenges and Opportunities","volume":"12","author":"Ozsolak","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"995061","DOI":"10.3389\/fphar.2022.995061","article-title":"Role of CD40(L)-TRAF Signaling in Inflammation and Resolution\u2014A Double-Edged Sword","volume":"13","author":"Strohm","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00022744-200106000-00001","article-title":"CD79: A Review","volume":"9","author":"Chu","year":"2001","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00262-008-0474-9","article-title":"CD54 Is a Surrogate Marker of Antigen Presenting Cell Activation","volume":"57","author":"Sheikh","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1074-7613(00)80615-9","article-title":"A Novel Lysosome-Associated Membrane Glycoprotein, DC-LAMP, Induced upon DC Maturation, Is Transiently Expressed in MHC Class II Compartment","volume":"9","author":"Vincent","year":"1998","journal-title":"Immunity"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2017-03-768507","article-title":"CD177 Modulates Human Neutrophil Migration through Activation-Mediated Integrin and Chemoreceptor Regulation","volume":"130","author":"Bai","year":"2017","journal-title":"Blood"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/19\/2365\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:59:08Z","timestamp":1760129948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/19\/2365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":42,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cells12192365"],"URL":"https:\/\/doi.org\/10.3390\/cells12192365","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}